Aigen Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28,058	Closed	-$219K	–	532
2025 Q4	$219K	Sell	28,058 -72,345	-72%	-$523K	0.05%	456
2025 Q3	$762K	Buy	100,403 +47,598	+90%	+$396K	0.12%	266
2025 Q2	$473K	Buy	+52,805	New	+$492K	0.06%	413
2024 Q4	–	Sell	-28,661	Closed	-$218K	–	735
2024 Q3	$218K	Buy	28,661 +12,280	+75%	+$93.3K	0.04%	559
2024 Q2	$101K	Sell	16,381 -24,720	-60%	-$136K	0.02%	699
2024 Q1	$209K	Buy	41,101 +28,431	+224%	+$160K	0.05%	536
2023 Q4	$75.9K	Sell	12,670 -140,804	-92%	-$816K	0.01%	740
2023 Q3	$1.09M	Buy	153,474 +75,179	+96%	+$540K	0.2%	146
2023 Q2	$551K	Buy	78,295 +35,772	+84%	+$287K	0.08%	326
2023 Q1	$355K	Buy	+42,523	New	+$409K	0.05%	392
2022 Q2	–	Sell	-11,172	Closed	-$182K	–	530
2022 Q1	$182K	Buy	+11,172	New	+$179K	0.03%	473
2021 Q2	–	Sell	-21,588	Closed	-$220K	–	475
2021 Q1	$220K	Buy	+21,588	New	+$223K	0.03%	514
2020 Q3	–	Sell	-13,984	Closed	-$67K	–	858
2020 Q2	$67K	Buy	+13,984	New	+$55.8K	0.01%	770